Momenta Pharmaceuticals Inc.
675 West Kendall Street
Cambridge,
MA 02142
United States - Map
Phone: 617-491-9700
Fax: 617-491-9701
Web Site: http://www.momentapharma.com
| Momenta Pharmaceuticals, Inc., a biotechnology company, specializes in the structural analysis of complex mixture drugs. The company applies its technology to the development of generic versions of complex drug products, as well as to the discovery and development of novel drugs. Its products include M-Enoxaparin, a technology-enabled generic version of Lovenox that is used to prevent and treat deep vein thrombosis and to support the treatment of acute coronary syndromes; and M356, a technology-enabled generic version of Copaxone, which is used for the reduction of the frequency of relapses in patients with relapse-remitting multiple sclerosis. The company is also developing M178 and M249, which are generic or follow-on versions of marketed therapeutic proteins. In addition, its products comprise M118, a low molecular weight heparin that is in Phase I clinical trial to support the treatment of patients diagnosed with ACS and stable angina; and glycoprotein drugs. Momenta Pharmaceuticals has collaborations with Sandoz N.V. and Sandoz, Inc. to develop and commercialize injectable enoxaparin. The company was founded in 2001. It was formerly known as Mimeon, Inc. and changed its name to Momenta Pharmaceuticals, Inc. in 2002. Momenta Pharmaceuticals is based in Cambridge, Massachusetts. |
|
| Key Statistics |
| |
| | Pay | Exercised | Mr. Craig A. Wheeler , 47
Chief Exec. Officer, Pres and Exec. Director |
N/A
| N/A | Dr. Ganesh Venkataraman Ph.D., 41
Co-Founder, Chief Scientific Officer and Sr. VP of Research |
N/A
| N/A | Dr. Ram Sasisekharan Ph.D., 43
Co-Founder, Member of Scientific Advisory Board, Director and Member of Science Committee |
N/A
| N/A | Mr. Richard P. Shea , 56
Chief Financial Officer, Principal Accounting Officer and Sr. VP |
N/A
| N/A | Mr. Steven B. Brugger , 49
Chief Operating Officer |
N/A
| N/A |
|
|
|
Dollar amounts are as of
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
0.29% Nasdaq 
0.14%
Profile
